Drug profile · INN
vamorolone
AGAMREE
vamorolone (AGAMREE) is a mineralocorticoid receptor antagonist. Associated with CATALYST PHARMACEUTICALS, INC.. Route of administration: oral. Current US regulatory status: approved.
Drug details — vamorolone
- US status
- approved
- Class
- Systemic hormonal preparations (H02)
- Route
- ORAL
- Patents
- 20
- Programs
- 3
- Data quality
- 0.89
Quick answer
vamorolone (AGAMREE) is a mineralocorticoid receptor antagonist. Associated with CATALYST PHARMACEUTICALS, INC.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Mineralocorticoid receptor antagonist
Primary target: Glucocorticoid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12201639
Aqueous oral pharmaceutical suspension compositions
granted -
US 11833159
Non-hormonal steroid modulators of NF-kB for treatment of disease
granted -
US 11806421
Porous-cellulose particles and production method thereof, and cosmetic
granted -
US 11690853
Non-hormonal steroid modulators of NF-κβ for treatment of disease
granted -
US 11471471
Aqueous oral pharmaceutical suspension compositions
granted -
US 11384062
Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
granted -
US 11382922
Aqueous oral pharmaceutical suspension compositions
granted -
US 11020326
Hollow particles and cosmetic
granted -
US 10857161
Non-hormonal steroid modulators of NF-kB for treatment of disease
granted -
US 10314769
Organic-inorganic composite particles and cosmetic product
granted -
US 10143636
Porous silica particle and cleansing cosmetic
granted -
US 9889072
Porous silica particle, method for producing the same, and cleansing cosmetic containing the same
granted -
US 9855195
Dental curable composition
granted -
US 9808407
Porous silica particle, method for producing the same, and cosmetic containing the same
granted -
US 9327258
Porous silica-based particles having smooth surface, method for production thereof and cosmetic comprising such particles
granted -
US 9254274
Method of treating Tourette'S disorder with GABA-aminotransferase inactivators
granted -
US 9011888
Organic-inorganic composite particles, process for producing the same, dispersion containing the particles, and cosmetic containing the particles
granted -
US 8969413
Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
granted -
US 8455564
Dental composition and composite resin
granted -
US 8440739
Dental composition and composite resin
granted
Frequently asked questions
What is vamorolone?
vamorolone (AGAMREE) is a mineralocorticoid receptor antagonist. Associated with CATALYST PHARMACEUTICALS, INC.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vamorolone?
AGAMREE is a marketed brand name for vamorolone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vamorolone?
vamorolone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.